GLP-1 medications can alter bowel movements, with constipation and diarrhea being the most common side effects. These drugs slow digestion to help control appetite, which can lead to changes in stool ...

A new study finds quitting GLP-1 drugs like Ozempic can reverse health gains and increase heart health risks. Patients who stopped taking the medication saw a higher risk for heart attack, stroke, or ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. GLP-1s are ...

If you happen to sit next to Mima Mendoza on a train or stand behind her in a checkout line, you might get an earful about the benefits of lifting weights. “I’ve become like the person at the train ...

One major benefit of taking injected GLP-1 medications is a sizeable reduction in risk for heart attacks, strokes and other heart problems. However, if people stop taking the medication, those heart ...

Glucagon-like peptide-1 (GLP-1) medications are now available as a pill for weight loss, offering another option beyond injections. Like the injections, GLP-1 pills can help regulate your appetite, ...

GLP-1 receptor agonists were associated with reduced risk of alcohol, cannabis, cocaine, nicotine and opioid use disorders, as well as other substance use disorders, suggesting potential prevention ...

Investigators tried to draw direct comparisons between GLP-1 receptor agonists versus bariatric surgery in patients undergoing Afib ablation using a retrospective cohort study. Findings gave GLP-1 ...

People who stop taking popular weight-loss and diabetes medications may lose out on any heart health benefits the medications provided. GLP-1 receptor agonists — such as semaglutide (Ozempic and ...

People take GLP-1 drugs like Wegovy, Ozempic, Mounjaro, and Zepbound for a variety of reasons, from controlling diabetes and sleep apnea to managing weight and enjoying benefits to the heart, liver, ...

Add Futurism (opens in a new tab) Adding us as a Preferred Source in Google by using this link indicates that you would like to see more of our content in Google News results. But new research ...

GLP-1 receptor agonists have seen far greater traction in the US than in Europe. Uptake of the drugs is already at around 12% in the US, according to the Dutch bank ING. However, in the EU and UK, ...